Amanda Lewton, MD
Family Medicine · Neosho, MONPI 1922329382
Payments from drug & device makers
Across 148 payments — averaging $13.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$412
- AstraZeneca$349
- Pfizer$268
- Amgen$128
- Boehringer Ingelheim$107
- Lilly USA, LLC$85
- plus $718 from 21 others
What the payments were for
- Food & beverage$2,066100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 38 | $412 |
| AstraZeneca | 19 | $349 |
| Pfizer | 27 | $268 |
| Amgen | 7 | $128 |
| Boehringer Ingelheim | 7 | $107 |
| Lilly USA, LLC | 5 | $85 |
| Novartis | 5 | $84 |
| GSK | 4 | $66 |
| Otsuka America Pharmaceutical, Inc. | 4 | $64 |
| Novo Nordisk | 4 | $63 |
| Merck | 3 | $53 |
| Johnson & Johnson | 3 | $44 |
| Sumitomo Pharma America, Inc. | 3 | $38 |
| Bayer | 2 | $34 |
| Ultragenyx Pharmaceutical Inc. | 2 | $33 |
| Abbott | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Nestle Healthcare Nutrition Inc. | 2 | $28 |
| Astellas Pharma US Inc | 1 | $24 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Exact Sciences | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $13 |
How this compares
$2,067 in reported general payments places this provider in the 75th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 114 | $130,429 |
| OzempicSemaglutide | 70 | $84,581 |
| JardianceEmpagliflozin | 77 | $69,909 |
| EliquisApixaban | 58 | $54,123 |
| MounjaroTirzepatide | 22 | $37,907 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $32,877 |
| TrulicityDulaglutide | 20 | $24,037 |
| MyrbetriqMirabegron | 29 | $19,651 |
| Xtampza ErOxycodone Myristate | 22 | $19,395 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $17,528 |
| BelsomraSuvorexant | 31 | $16,126 |
| LinzessLinaclotide | 18 | $14,888 |
| Spiriva HandihalerTiotropium Bromide | 18 | $11,382 |
| XareltoRivaroxaban | 15 | $11,355 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 353 | $11,245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $349 | $147,957139 claims |
| Novo NordiskOzempic | $63 | $84,58170 claims |
| Boehringer IngelheimJardiance | $107 | $69,90977 claims |
| Lilly USA, LLCMounjaro, Trulicity | $85 | $61,94442 claims |
| PfizerEliquis, Abrysvo | $268 | $59,45479 claims |
| GSKTrelegy Ellipta, Arexvy | $66 | $37,28046 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $19,65129 claims |
| MerckBelsomra | $53 | $16,12631 claims |
| AbbVieLinzess | $412 | $14,88818 claims |
| Johnson & JohnsonXarelto | $44 | $11,35515 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $38 | $7,15712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Neosho
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.